Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.

FDA Approves Ibtrozi For Adults With ROS1+ NSCLC

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, according to the results of a news release.

FDA Approves Ibtrozi (taletrectinib) for ROS1-positive NSCLC  - GO2 for Lung Cancer

Open the article to view the coverage from go2.org

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Taletrectinib demonstrated high response rates and was well-tolerated among patients with ROS1+ non-small cell lung cancer (NSCLC).